CN117503441B - Recoverable medicine support and support system - Google Patents
Recoverable medicine support and support system Download PDFInfo
- Publication number
- CN117503441B CN117503441B CN202410021621.1A CN202410021621A CN117503441B CN 117503441 B CN117503441 B CN 117503441B CN 202410021621 A CN202410021621 A CN 202410021621A CN 117503441 B CN117503441 B CN 117503441B
- Authority
- CN
- China
- Prior art keywords
- stent
- recovery
- support
- column
- sheath
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 229940079593 drug Drugs 0.000 claims abstract description 24
- 230000002787 reinforcement Effects 0.000 claims abstract 8
- 238000011084 recovery Methods 0.000 claims description 45
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 239000012867 bioactive agent Substances 0.000 claims description 7
- -1 acipimab Chemical compound 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 6
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 6
- 229960002930 sirolimus Drugs 0.000 claims description 6
- 239000003146 anticoagulant agent Substances 0.000 claims description 5
- 238000005520 cutting process Methods 0.000 claims description 4
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims description 3
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- 102000007625 Hirudins Human genes 0.000 claims description 3
- 108010007267 Hirudins Proteins 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 230000001028 anti-proliverative effect Effects 0.000 claims description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- 229940034982 antineoplastic agent Drugs 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229960004676 antithrombotic agent Drugs 0.000 claims description 3
- 229960003957 dexamethasone Drugs 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- 229960001123 epoprostenol Drugs 0.000 claims description 3
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 claims description 3
- 229960005167 everolimus Drugs 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 3
- 229940006607 hirudin Drugs 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 229960004584 methylprednisolone Drugs 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- 229960001967 tacrolimus Drugs 0.000 claims description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 229950009819 zotarolimus Drugs 0.000 claims description 3
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 claims description 3
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229960002594 arsenic trioxide Drugs 0.000 claims description 2
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000006073 displacement reaction Methods 0.000 claims 1
- 210000003708 urethra Anatomy 0.000 abstract description 23
- 230000006835 compression Effects 0.000 abstract description 3
- 238000007906 compression Methods 0.000 abstract description 3
- 238000002513 implantation Methods 0.000 abstract description 3
- 210000002700 urine Anatomy 0.000 abstract description 3
- 230000004663 cell proliferation Effects 0.000 abstract description 2
- 230000003014 reinforcing effect Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
- 206010065584 Urethral stenosis Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 201000001988 urethral stricture Diseases 0.000 description 3
- 229910000831 Steel Inorganic materials 0.000 description 2
- 238000004026 adhesive bonding Methods 0.000 description 2
- 238000013532 laser treatment Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 206010061876 Obstruction Diseases 0.000 description 1
- 208000028938 Urination disease Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940091658 arsenic Drugs 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000002788 crimping Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011471 prostatectomy Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/848—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/92—Stents in the form of a rolled-up sheet expanding after insertion into the vessel, e.g. with a spiral shape in cross-section
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
- A61F2/9522—Means for mounting a stent or stent-graft onto or into a placement instrument
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
- A61F2/962—Instruments specially adapted for placement or removal of stents or stent-grafts having an outer sleeve
- A61F2/966—Instruments specially adapted for placement or removal of stents or stent-grafts having an outer sleeve with relative longitudinal movement between outer sleeve and prosthesis, e.g. using a push rod
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2002/821—Ostial stents
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
The invention discloses a recoverable drug stent and a stent system, wherein the stent is elastic, the stent comprises a support column, a reinforcement column and a fixed anchor, the support column and the reinforcement column are provided with a plurality of support columns, the reinforcement column connects two adjacent support columns, in the invention, the stent is used for expanding and remodelling the prostatic urethra by minimally invasive implantation, the stent does not need to burn or cut the prostatic urethra, and then is left in a patient for 5 to 7 days, during the period, the stent can open the prostatic urethra by self expansion force, so that urine can smoothly flow and discharge, the drug on the stent is transferred to an expansion area, the cell proliferation caused by the compression and expansion of the stent is restrained, simultaneously, the prostatic urethra is remodelled, the urethra is kept smooth, and the drug release is completed.
Description
Technical Field
The invention relates to the technical field of medical instruments, in particular to a recyclable drug stent and a stent system.
Background
Prostatic hyperplasia is the most common disease causing urination disorder of middle-aged and elderly men, and the treatment method of prostatic hyperplasia comprises conventional surgical treatment, laser treatment and minimally invasive interventional treatment.
The current treatment methods for prostatic hyperplasia have a plurality of defects:
1. in the conventional surgical treatment, the wound surface is difficult to stop bleeding due to thinner solidification, the wound surface is more easily scabbed due to high temperature in the operation to influence the operation visual field, further serious complication risks are brought, and complications such as injury and urethral stricture are reported due to high temperature.
2. If the laser operation of a doctor is not skilled in the laser treatment, the adjacent organs of the patient can be damaged; it is costly compared to traditional prostatectomy, and a few patients after surgery can have sexual function effects.
3. The minimally invasive interventional therapy is a method for opening a prostatic urethra cavity and realizing urination by introducing a bracket and supporting prostatic tissues by the bracket, and because the minimally invasive interventional therapy is placed in a human body for a long time, the minimally invasive interventional therapy can displace after a certain time, thereby causing adverse effects on the using effect, the taking out and the like of the bracket, and having high urinary tract obstruction risks at the later stage of the taking out of the bracket.
Disclosure of Invention
In order to solve the technical problems, the invention provides a recyclable drug stent, which is elastic, the stent is formed by cutting a tube, the stent comprises a support column, a reinforcing column and a fixed anchor, the distal end of the fixed anchor is connected with the proximal end of the support column, the fixed anchor is in a spiral design, the support column and the reinforcing column are provided with a plurality of support columns, the reinforcing column connects two adjacent support columns, and the proximal end of the stent is provided with an inner hole.
Preferably: the stent surface is coated with a drug coating comprising a bioactive agent.
Preferably: the bioactive agent is selected from one or a combination of at least two of antineoplastic agent, antiproliferative agent, antibiotic, anticoagulant, antithrombotic agent, and anti-inflammatory agent.
Preferably: the components of the drug coating are selected from any one or a combination of at least two of sirolimus, paclitaxel, arsenic trioxide, zotarolimus, heparin, everolimus, tacrolimus or rapamycin, hirudin, prostacyclin, acipimab, dexamethasone, methylprednisolone and biphosphate liposome.
Preferably: the support is polygonal, and the side section of the support is in an acute isosceles triangle shape.
Preferably: the reinforcing column and the supporting column are integrally formed, and the middle part of the reinforcing column is designed to be an acute angle.
A stent system for delivering and retrieving stents.
Preferably: the support system comprises a boosting pipe, a recovery line and a conveying sheath, wherein the tail end of the boosting pipe can be inserted into an inner hole, the boosting pipe is rotated and drives the support to rotate together, and the conveying sheath is movably sleeved on the boosting pipe and is used for wrapping the support.
Preferably: the stent system further comprises a recovery system comprising a recovery sheath and a recovery wire, the recovery wire is used for enabling the recovery wire to pass through the recovery sheath, the recovery sheath is used for wrapping the stent, and the stent is contracted into the recovery sheath.
The invention has the technical effects and advantages that:
1. in the invention, the stent is implanted into the prostatic urethra in a minimally invasive implantation mode for expanding and remodelling the prostatic urethra without burning or cutting the prostatic, and then the stent is left in a patient for 5 to 7 days, and during the period, the stent can open the prostatic urethra by self expansion force, so that urine can smoothly flow and discharge.
2. In the invention, the medicine on the stent is transferred to the expansion area, so that the cell proliferation caused by the compression and expansion of the stent on the urethra is inhibited, and simultaneously, the prostatic urethra is remodelled, the urethra is kept smooth, and the medicine is released completely.
3. According to the invention, the whole stent system is withdrawn from the body through the recovery system, the medicine is continuously stored in the body for more than 28 days, the prostatic urethra is continuously remodelled, and the obstructive symptom of the urinary tract of a patient can be rapidly relieved and improved for a long time.
Drawings
Fig. 1 is a schematic structural view of a novel medical stent provided in an embodiment of the present application;
FIG. 2 is a schematic structural view of a stent system provided in an embodiment of the present application;
FIG. 3 is an enlarged schematic view of the structure at A in FIG. 2 in a stent system provided in an embodiment of the present application;
FIG. 4 is an enlarged schematic view of the structure at B in FIG. 2 of the stent system provided in an embodiment of the present application;
FIG. 5 is a schematic view of a recovery system in a rack system according to an embodiment of the present application;
fig. 6 is a schematic view of a connection structure of a stent and a recycled steel wire in a stent system according to an embodiment of the present application.
In the figure: 1. a stent system; 10. a bracket; 11. a support column; 12. a reinforcing column; 13. fixing anchors; 14. an inner bore; 20. a boosting pipe; 30. a recovery line; 40. a delivery sheath; 50. a recovery system; 51. recovering the sheath; 52. and (5) recovering the steel wire.
Detailed Description
The invention will be described in further detail with reference to the drawings and the detailed description. The embodiments of the invention have been presented for purposes of illustration and description, and are not intended to be exhaustive or limited to the invention in the form disclosed. Many modifications and variations will be apparent to those of ordinary skill in the art. The embodiments were chosen and described in order to best explain the principles of the invention and the practical application, and to enable others of ordinary skill in the art to understand the invention for various embodiments with various modifications as are suited to the particular use contemplated.
Referring to fig. 1, in the present invention, there is provided a recyclable drug stent, wherein the stent 10 is elastic and can be contracted into a contracted configuration, wherein the stent 10 is cut from a tube, wherein all proximal ends of the stent 10 are connected to each other, and all distal ends of the stent are connected to each other.
In the present embodiment, the bracket 10 includes a support column 11, a reinforcing column 12, and a fixing anchor 13, the support column 11 and the reinforcing column 12 being provided in plurality, the reinforcing column 12 connecting the support columns 11 of adjacent two, the reinforcing column 12 providing a supporting force to the support column 11.
Preferably, the reinforcing column 12 is integrally formed with the support column 11, thereby greatly improving the strength of the reinforcing column 12 and the support column 11.
In this embodiment, the stent 10 is polygonal, the side section of the stent 10 is in the shape of an acute isosceles triangle, specifically, the middle part of the reinforcing column 12 is designed to be an acute angle, and the reinforcing column 12 is easier to deform during recovery, so that the stent 10 is conveniently compressed into the delivery sheath 40 and the recovery sheath 51.
In this embodiment, the distal end of the anchor 13 is connected to the proximal end of the support post 11, and the anchor 13 is made of a material including, but not limited to, wire and serves to prevent the medical stent 10 from being displaced in the distal direction.
Specifically, the anchor 13 is in a spiral design, the spiral structure may be a circular or polygonal structure, so that the stent 10 is conveniently contracted into the delivery sheath 40 or the recovery sheath 51, and the spiral shape of the anchor 13 is recovered when the anchor 13 is contracted into the delivery sheath 40 or the recovery sheath 51, and the spiral shape is contracted into a straight line shape when the anchor 13 is moved out of the delivery sheath 40 or the recovery sheath 51 due to the elasticity of the spiral-shaped anchor 13.
In this embodiment, the proximal end of the support post 11 is attached to the proximal end of the anchor 13 by means including, but not limited to, crimping, gluing, and welding.
In the present invention, a drug coating for a recyclable drug stent is provided for application to the stent 10, the drug coating comprising a bioactive agent or bioactive agent and a carrier.
Specifically, the bioactive agent is selected from the group consisting of, but not limited to, antineoplastic agents, antiproliferatives, antibiotics, anticoagulants, antithrombotics, and anti-inflammatory agents.
Specifically, the components of the drug coating include, but are not limited to, any one or a combination of at least two of sirolimus, paclitaxel, arsenic, zotarolimus, heparin, everolimus, tacrolimus or rapamycin, hirudin, prostacyclin, acipimab, dexamethasone, methylprednisolone and biphosphate liposome.
In particular, the drug coating may be applied to the stent 10 by spray coating or dip coating.
In particular, the carrier may be an absorbable biocompatible material or polymer.
The stent 10 is placed in the prostatic urethra in a minimally invasive implantation mode, is used for dilating and remodelling the prostatic urethra without burning or cutting the prostatic urethra, and is then left in a patient for 5 to 7 days, the stent 10 opens the prostatic urethra through self-expanding force, urine can smoothly flow and discharge, medicines on the stent 10 are transferred to an expansion area, the proliferation of cells caused by the compression and expansion of the stent 10 is inhibited, the prostatic urethra is remodelled and kept smooth, the stent 10 is recovered after the release of the medicines is finished, the medicines are continuously stored in the body for more than 28 days after being withdrawn from the whole stent system, and the obstruction symptoms of the urinary tract of the patient can be relieved and improved quickly.
Further, the proximal end of the stent 10 is provided with an inner bore 14, and the inner bore 14 is of polygonal or circular design.
Referring to fig. 2 to 4, in this embodiment, a stent system for a recyclable drug stent is provided, wherein the stent system 1 comprises a booster tube 20, a recycling line 30 and a delivery sheath 40, and the tail end of the booster tube 20 can be inserted into the inner hole 14, so that the booster tube 20 can be rotated while the stent 10 is rotated together.
Specifically, the recovery wire 30 is connected to the proximal end of the support 10, and may be connected by riveting or gluing, and passes through the inner hole of the booster tube 20, and knotting is performed on the proximal end of the booster tube 20.
Specifically, the delivery sheath 40 is movably sleeved on the booster tube 20 and is used for wrapping the stent 10, the stent 10 can be contracted into the delivery sheath 40, the proximal end of the delivery sheath 40 is provided with a blade-shaped handle, the blade-shaped handle is convenient to operate, the delivery sheath 40 is prevented from following the stent 10 to penetrate into human tissues when the stent 10 is placed, the success rate of placement of the delivery sheath 40 is improved, the diameter of an inner hole at the proximal end of the delivery sheath 40 is similar to that of the booster tube 20, and bladder can not reach a filling state in the process of placing the stent 10 is prevented.
Referring to fig. 5 to 6, in the present embodiment, the stent system 1 further includes a recovery system 50, the recovery system 50 including a recovery sheath 51 and a recovery wire 52, the recovery wire 52 for passing the recovery wire 30 through the recovery sheath 51, the recovery sheath 51 for wrapping the stent 10, contracting the stent 10 into the recovery sheath 51, and removing the body, thereby facilitating the removal of the stent 10 from the recovery sheath 51.
Further, the proximal end of the recovery sheath 51 is provided with a handle, which is provided in a blade shape, and in the recovery process, the recovery sheath 51 is convenient to operate.
Before the stent system is used, the boosting pipe 20 is inserted into the inner hole of the stent 10, the recovery line 30 passes through the inner hole of the boosting pipe 20 and is knotted at the proximal end of the boosting pipe 20, and then the boosting pipe 20 is inserted into the delivery sheath 40, so that the stent 10 is contracted into the delivery sheath 40, and the stent 10 is in a contracted state;
when in use, the delivery sheath 40 and the boosting tube 20 are implanted into the prostatic urethra, the stent 10 is positioned at the inner side of the urethral stricture, the delivery sheath 40 is taken out, after the delivery sheath 40 is separated from the stent 10, the stent 10 is in an open state, the taken-out delivery sheath 40 is further implanted into the prostatic urethra and positioned at the outer side of the boosting tube 20, and is used for expanding the prostatic urethra, the boosting tube 20 is pulled outwards, the opened stent 10 is moved to the urethral stricture to play a supporting role, the proximal end of the boosting tube 20 is sheared off and the knot of the recovery line 30 is cut off, the boosting tube 20 is taken out, after the boosting tube 20 is separated from the stent 10, the stent 10 is in an open state, and the proximal end of the recovery line 30 is positioned at the urethral outer side;
after the prostatic urethra has been remodelled, the retrieval wire 52 is secured to the proximal end of the retrieval wire 30, the retrieval wire 52 and the retrieval wire 30 are passed through the retrieval sheath 51, the retrieval sheath 51 is implanted into the prostatic urethra, the stent 10 is retracted into the retrieval sheath 51 and the body is removed.
It will be apparent that the described embodiments are only some, but not all, embodiments of the invention. All other embodiments, which can be made by those skilled in the art and which are included in the embodiments of the present invention without the inventive step, are intended to be within the scope of the present invention. Structures, devices and methods of operation not specifically described and illustrated herein, unless otherwise indicated and limited, are implemented according to conventional means in the art.
Claims (9)
1. Recoverable medicine support, support (10) have elasticity, its characterized in that, support (10) are formed by tubular product cutting, support (10) are including support column (11), reinforcement column (12) and anchor (13), and the distal end of anchor (13) is connected with the proximal end of support column (11), and anchor (13) are spiral design, and anchor (13) are made by the silk material for prevent support (10) to produce the displacement to distal end direction, support column (11) and reinforcement column (12) are provided with a plurality ofly, and reinforcement column (12) connect two adjacent support columns (11), the proximal end of support column (11) gathers and forms hole (14), and hole (14) are used for inserting booster tube (20).
2. The recyclable drug stent according to claim 1, characterized in that the stent (10) surface is coated with a drug coating comprising a bioactive agent.
3. The recyclable drug stent of claim 2, wherein the bioactive agent is selected from one or a combination of at least two of an antineoplastic agent, an antiproliferative agent, an antibiotic, an anticoagulant, an antithrombotic agent, and an anti-inflammatory agent.
4. The recyclable drug stent of claim 2, wherein the components of the drug coating are selected from any one or a combination of at least two of sirolimus, paclitaxel, arsenic trioxide, zotarolimus, heparin, everolimus, tacrolimus, or rapamycin, hirudin, prostacyclin, acipimab, dexamethasone, methylprednisolone, biphosphate liposomes, or a combination of at least two.
5. The recyclable drug stent according to claim 1, characterized in that the stent (10) is polygonal in shape, and the stent (10) side cross section is in the shape of an acute isosceles triangle.
6. The recyclable drug stent as defined in claim 1, wherein the reinforcement column (12) and the support column (11) are integrally formed, and a middle portion of the reinforcement column (12) is designed as an acute angle.
7. A stent system, characterized in that the stent system (1) is used for transporting and retrieving a stent (10) according to any one of claims 1-6.
8. The stent system according to claim 7, wherein the stent system (1) comprises a booster tube (20), a recovery wire (30) and a delivery sheath (40), wherein the tail end of the booster tube (20) is insertable into the inner bore (14), the booster tube (20) is rotated while simultaneously driving the stent (10) to rotate together, and the delivery sheath (40) is movably sleeved on the booster tube (20) and is used for wrapping the stent (10).
9. The stent system according to claim 8, wherein the stent system (1) further comprises a recovery system (50), the recovery system (50) comprising a recovery sheath (51) and a recovery wire (52), the recovery wire (52) being for passing a recovery wire (30) through the recovery sheath (51), the recovery sheath (51) being for wrapping the stent (10), shrinking the stent (10) into the recovery sheath (51).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410021621.1A CN117503441B (en) | 2024-01-08 | 2024-01-08 | Recoverable medicine support and support system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410021621.1A CN117503441B (en) | 2024-01-08 | 2024-01-08 | Recoverable medicine support and support system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117503441A CN117503441A (en) | 2024-02-06 |
| CN117503441B true CN117503441B (en) | 2024-03-29 |
Family
ID=89755448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410021621.1A Active CN117503441B (en) | 2024-01-08 | 2024-01-08 | Recoverable medicine support and support system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117503441B (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN205107973U (en) * | 2015-11-03 | 2016-03-30 | 柏为（武汉）医疗科技有限公司 | Recoverable medicine vena cave filter of scribbling that adherence nature is good |
| CN106073942A (en) * | 2015-04-30 | 2016-11-09 | 微创心脉医疗科技（上海）有限公司 | A kind of support and delivery device |
| CN107496006A (en) * | 2017-09-22 | 2017-12-22 | 南京普微森医疗科技有限公司 | Take thrombus support |
| CN109452992A (en) * | 2018-11-21 | 2019-03-12 | 先健科技(深圳)有限公司 | Stoma instrument |
| CN110584849A (en) * | 2019-10-14 | 2019-12-20 | 江苏诺瑞思医疗器械有限公司 | Shape memory alloy coated anchor bracket and manufacturing method thereof |
| CN113288504A (en) * | 2021-03-25 | 2021-08-24 | 上海惠凯医疗科技有限公司 | Easily retrieve high strength urethra support |
| CN216439802U (en) * | 2020-12-17 | 2022-05-06 | 首都医科大学附属北京安贞医院 | Anti-drop bacterinertness ureter support |
| CN117100470A (en) * | 2023-06-09 | 2023-11-24 | 上海恩盛医疗科技有限公司 | Vascular stent |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6811560B2 (en) * | 2001-09-20 | 2004-11-02 | Cordis Neurovascular, Inc. | Stent aneurysm embolization method and device |
| US20050165469A1 (en) * | 2002-12-24 | 2005-07-28 | Michael Hogendijk | Vascular prosthesis including torsional stabilizer and methods of use |
| US20080004692A1 (en) * | 2006-06-28 | 2008-01-03 | Henson Michael R | Dynamically adjustable vascular stent |
| US20210145580A1 (en) * | 2018-08-07 | 2021-05-20 | 4Tech Inc. | Post-implantation tensioning in cardiac implants |
-
2024
- 2024-01-08 CN CN202410021621.1A patent/CN117503441B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106073942A (en) * | 2015-04-30 | 2016-11-09 | 微创心脉医疗科技（上海）有限公司 | A kind of support and delivery device |
| CN205107973U (en) * | 2015-11-03 | 2016-03-30 | 柏为（武汉）医疗科技有限公司 | Recoverable medicine vena cave filter of scribbling that adherence nature is good |
| CN107496006A (en) * | 2017-09-22 | 2017-12-22 | 南京普微森医疗科技有限公司 | Take thrombus support |
| CN109452992A (en) * | 2018-11-21 | 2019-03-12 | 先健科技(深圳)有限公司 | Stoma instrument |
| CN110584849A (en) * | 2019-10-14 | 2019-12-20 | 江苏诺瑞思医疗器械有限公司 | Shape memory alloy coated anchor bracket and manufacturing method thereof |
| CN216439802U (en) * | 2020-12-17 | 2022-05-06 | 首都医科大学附属北京安贞医院 | Anti-drop bacterinertness ureter support |
| CN113288504A (en) * | 2021-03-25 | 2021-08-24 | 上海惠凯医疗科技有限公司 | Easily retrieve high strength urethra support |
| CN117100470A (en) * | 2023-06-09 | 2023-11-24 | 上海恩盛医疗科技有限公司 | Vascular stent |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117503441A (en) | 2024-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6447540B1 (en) | Stent deployment device including splittable sleeve containing the stent | |
| US5669924A (en) | Y-shuttle stent assembly for bifurcating vessels and method of using the same | |
| EP1926453B1 (en) | Catheter for Placement of a Stent | |
| US7131986B2 (en) | Catheter having exchangeable balloon | |
| US5807398A (en) | Shuttle stent delivery catheter | |
| US20180021156A1 (en) | Varying diameter vascular implant and balloon | |
| JP2999731B2 (en) | Device comprising a graft or prosthesis and a catheter | |
| JP2933226B2 (en) | Stretchable endoluminal vascular graft and device for extending the lumen of a body passage | |
| JP2680901B2 (en) | Extendable endoluminal implant | |
| US7238168B2 (en) | Exchangeable catheter | |
| US20050131526A1 (en) | Stent and balloon system for bifurcated vessels and lesions | |
| US8156942B2 (en) | Method of implanting a transmyocardial stent | |
| US20140066898A1 (en) | Retractable sheath devices, systems, and methods | |
| WO1997015346A9 (en) | Y-shuttle stent assembly for bifurcating vessels | |
| EP2928537A1 (en) | Balloon catheter and methods of use thereof | |
| JP5074502B2 (en) | Self-expanding stent system for bifurcated damage | |
| JP2003521971A (en) | Method and apparatus for protecting passages in the body | |
| WO2012006124A2 (en) | Method and apparatus for the endoluminal delivery of intravascular devices | |
| JP2007511317A (en) | Vascular implant | |
| JPH0623057A (en) | Stent feeding system | |
| US20120101560A1 (en) | Retractable flow maintaining stent wire | |
| JP2002507930A (en) | Expandable support device with disease inhibitor and method of using same | |
| US7753876B2 (en) | Expandable jaw drug delivery catheter | |
| US20150073526A1 (en) | Retractable Flow Maintaining Stent | |
| CN117503441B (en) | Recoverable medicine support and support system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |